Effectiveness and cost-effectiveness of treatment with additional enrollment to a homeopathic integrated care contract in Germany

Table 4 Diagnosis-specific adjusted means of total costs over 12 months after baseline, insurer and secondary societal perspectives

	HOM group		CON group
Diagnosis	N Cost utilization	Adj. mean (€) (95% CI)	N Cost utilization	Adj. mean (€) (95% CI)	Group Δ*	p-value†
Insurer perspective (primary cost outcome)
Migraine/headache	422	1654.42 (1309.80–1999.04)	265	1231.30 (839.57–1623.02)	423.13	< 0.001
Allergic rhinitis	316	1137.50 (880.82–1394.17)	187	1038.28 (748.78–1327.79)	99.22	0.220
Asthma	123	1463.28 (938.27–1988.29)	80	722.83 (116.94–1328.73)	740.45	< 0.001
Atopic dermatitis	229	1269.32 (962.23–1576.40)	104	1129.83 (763.50–1496.17)	139.49	0.250
Depression	452	1974.63 (1703.83–2245.43)	341	1553.96 (1241.84–1866.08)	420.67	< 0.001
Societal perspective
Migraine/headache	422	4938.64 (2358.01–7519.28)	265	5010.48 (2077.35–7943.61)	−71,84	0.924
Allergic rhinitis	316	3073.44 (1125.04–5021.84)	187	3274.15 (1074.55–5473.74)	−200,71	0.744
Asthma	123	3022.62 (−43.81–6089.04)	80	1285.69 (−2244.58–4815.95)	1736,93	0.157
Atopic dermatitis	229	7353.94 (5070.56–9637.31)	104	7536.04 (4812.85–10,259.24)	−182,1	0.839
Depression	452	9402.39 (6182.19–12,622.59)	341	7207.43 (3499.95–10,914.90)	2194,96	0.078

* HOM group minus CON group, † adjusted for age, sex, education, residential state, complementary medicine affiliation, per protocol initial anamnesis, baseline utility value, total costs 12 months prior to baseline

ISSN: 1472-6963